SFRS17A inhibitors are a group of compounds that possess the theoretical capacity to inhibit SFRS17A, albeit indirectly. They achieve this by targeting a variety of cellular processes closely associated with pre-mRNA splicing and protein kinase A (PKA) signaling, both of which intersect with SFRS17A's functional domains. What these compounds share is their ability to exert an impact on these broader cellular mechanisms, thereby influencing SFRS17A's multifaceted functions. For instance, some compounds within this group, such as Actinomycin D and DRB, function as transcription inhibitors, diminishing the synthesis of pre-mRNA molecules. This reduction in pre-mRNA availability subsequently curtails the pool of substrates that SFRS17A can operate on, potentially leading to altered splicing patterns.
Moreover, some compounds intervene in spliceosome assembly and prompt changes in alternative splicing patterns. These disruptions can indirectly affect the precise splicing events where SFRS17A plays a pivotal role, potentially leading to deviations in the exon-intron boundaries it typically defines. Furthermore, certain compounds within this category possess the capability to regulate PKA activation. Given SFRS17A's role as an A-kinase anchoring protein (AKAP), its primary function is to guide PKA to specific cellular compartments, particularly within the context of splicing regulation. Consequently, any alterations in PKA activation can have a ripple effect on SFRS17A's interactions with PKA, consequently influencing its efficiency in regulating splicing. Collectively, these compounds serve as powerful tools that emphasize the intricate nature of SFRS17A's involvement in gene regulation and PKA signaling. Their ability to indirectly impact SFRS17A's regulatory function underscores the interconnectedness of the cellular processes that this protein is an integral part of. The development and use of SFRS17A inhibitors contribute significantly to the broader understanding of this protein and its role within the intricate framework of cellular biology, shedding light on its involvement in gene regulation and pre-mRNA splicing.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Actinomycin D | 50-76-0 | sc-200906 sc-200906A sc-200906B sc-200906C sc-200906D | 5 mg 25 mg 100 mg 1 g 10 g | $74.00 $243.00 $731.00 $2572.00 $21848.00 | 53 | |
Inhibits RNA polymerase, potentially reducing the transcription of pre-mRNA that serves as substrates for SFRS17A, potentially limiting its regulatory role in splicing. | ||||||
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Elevates cAMP levels, impacting PKA activation and localization, which could potentially alter SFRS17A's interaction with PKA and its role in splicing regulation. | ||||||
Triptolide | 38748-32-2 | sc-200122 sc-200122A | 1 mg 5 mg | $90.00 $204.00 | 13 | |
Affects splicing factor function and alternative splicing, potentially influencing the landscape of pre-mRNA splicing that SFRS17A participates in. | ||||||
Leptomycin B | 87081-35-4 | sc-358688 sc-358688A sc-358688B | 50 µg 500 µg 2.5 mg | $107.00 $416.00 $1248.00 | 35 | |
Alters cellular localization of proteins, potentially affecting SFRS17A's ability to target PKA to specific splicing factor compartments. | ||||||
DRB | 53-85-0 | sc-200581 sc-200581A sc-200581B sc-200581C | 10 mg 50 mg 100 mg 250 mg | $43.00 $189.00 $316.00 $663.00 | 6 | |
Inhibits transcription and mRNA processing, which might reduce the availability of pre-mRNA substrates for SFRS17A's regulatory role. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
Modulates PKA signaling, potentially influencing SFRS17A's interactions and function within the splicing factor compartments. | ||||||
Cisplatin | 15663-27-1 | sc-200896 sc-200896A | 100 mg 500 mg | $138.00 $380.00 | 101 | |
May impact splicing factor functions in splicing regulation, which could indirectly affect SFRS17A's role in defining exon-intron boundaries. | ||||||
Dexamethasone | 50-02-2 | sc-29059 sc-29059B sc-29059A | 100 mg 1 g 5 g | $91.00 $139.00 $374.00 | 36 | |
May affect the stability and transcription of mRNA transcripts, which could indirectly impact the availability of pre-mRNA substrates for SFRS17A. | ||||||